Literature DB >> 28801346

Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.

Jerome Avouac1,2, Irena Konstantinova3, Christophe Guignabert4,5, Sonia Pezet1, Jeremy Sadoine6, Thomas Guilbert1, Anne Cauvet1, Ly Tu4,5, Jean-Michel Luccarini3, Jean-Louis Junien3, Pierre Broqua3, Yannick Allanore1,2,6.   

Abstract

OBJECTIVE: To evaluate the antifibrotic effects of the pan-peroxisome proliferator-activated receptor (PPAR) agonist IVA337 in preclinical mouse models of pulmonary fibrosis and related pulmonary hypertension (PH).
METHODS: IVA337 has been evaluated in the mouse model of bleomycin-induced pulmonary fibrosis and in Fra-2 transgenic mice, this latter being characterised by non-specific interstitial pneumonia and severe vascular remodelling of pulmonary arteries leading to PH. Mice received two doses of IVA337 (30 mg/kg or 100 mg/kg) or vehicle administered by daily oral gavage up to 4 weeks.
RESULTS: IVA337 demonstrated at a dose of 100 mg/kg a marked protection from the development of lung fibrosis in both mouse models compared with mice receiving 30 mg/kg of IVA337 or vehicle. Histological score was markedly reduced by 61% in the bleomycin model and by 50% in Fra-2 transgenic mice, and total lung hydroxyproline concentrations decreased by 28% and 48%, respectively, as compared with vehicle-treated mice. IVA337 at 100 mg/kg also significantly decreased levels of fibrogenic markers in lesional lungs of both mouse models. In addition, IVA337 substantially alleviated PH in Fra-2 transgenic mice by improving haemodynamic measurements and vascular remodelling. In primary human lung fibroblasts, IVA337 inhibited in a dose-dependent manner fibroblast to myofibroblasts transition induced by TGF-β and fibroblast proliferation mediated by PDGF.
CONCLUSION: We demonstrate that treatment with 100 mg/kg IVA337 prevents lung fibrosis in two complementary animal models and substantially attenuates PH in the Fra-2 mouse model. These findings confirm that the pan-PPAR agonist IVA337 is an appealing therapeutic candidate for these cardiopulmonary involvements. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  IVA337; PPAR.; nuclear receptors; pulmonary fibrosis; pulmonary hypertension; systemic sclerosis

Mesh:

Substances:

Year:  2017        PMID: 28801346     DOI: 10.1136/annrheumdis-2016-210821

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

Review 1.  Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.

Authors:  Keshava Rajagopal; Andrew J Bryant; Sandeep Sahay; Nancy Wareing; Yang Zhou; Lavannya M Pandit; Harry Karmouty-Quintana
Journal:  Br J Pharmacol       Date:  2020-04-07       Impact factor: 8.739

Review 2.  Targeting fatty acid metabolism for fibrotic disorders.

Authors:  Seonghwan Hwang; Ki Wung Chung
Journal:  Arch Pharm Res       Date:  2021-10-18       Impact factor: 4.946

3.  Therapeutic molecular targets of SSc-ILD.

Authors:  Yun Zhang; Jörg Hw Distler
Journal:  J Scleroderma Relat Disord       Date:  2020-01-22

Review 4.  Group 3 Pulmonary Hypertension: From Bench to Bedside.

Authors:  Navneet Singh; Peter Dorfmüller; Oksana A Shlobin; Corey E Ventetuolo
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

Review 5.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

Review 6.  Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.

Authors:  Narendra S Choudhary; Naveen Kumar; Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2019-07-02

Review 7.  Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease.

Authors:  Ronan Thibaut; Matthew C Gage; Inès Pineda-Torra; Gwladys Chabrier; Nicolas Venteclef; Fawaz Alzaid
Journal:  FEBS J       Date:  2021-05-02       Impact factor: 5.622

Review 8.  Shared and distinct mechanisms of fibrosis.

Authors:  Jörg H W Distler; Andrea-Hermina Györfi; Meera Ramanujam; Michael L Whitfield; Melanie Königshoff; Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2019-11-11       Impact factor: 20.543

9.  Proteomics and metabonomics analyses of Covid-19 complications in patients with pulmonary fibrosis.

Authors:  Jianrong Yang; Chunxia Chen; Wan Chen; Luying Huang; Zhao Fu; Kun Ye; Liwen Lv; Zhihuang Nong; Xing Zhou; Wensheng Lu; Mei Zhong
Journal:  Sci Rep       Date:  2021-07-16       Impact factor: 4.379

Review 10.  Current and future pharmacological therapies for NAFLD/NASH.

Authors:  Yoshio Sumida; Masashi Yoneda
Journal:  J Gastroenterol       Date:  2017-12-16       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.